The online version of this article (doi:10.1007/s11136-016-1288-4) contains supplementary material, which is available to authorized users.
Epidermal growth factor receptor inhibitors such as panitumumab are associated with characteristic skin toxicities. We summarise data from three panitumumab clinical trials to investigate the potential impact of skin toxicity on quality of life (QoL) in patients with metastatic colorectal cancer (mCRC).
The studies were randomised, open-label trials comparing standard treatment (first-line FOLFOX4 [n = 456], second-line FOLFIRI [n = 381], or best supportive care [n = 114]) with or without panitumumab in adults with KRAS/NRAS (RAS) wild-type mCRC. QoL was assessed using the EuroQoL 5-domain health state index (HSI) and overall health rating (OHR) measures. Impact of skin toxicity on changes in QoL scores was estimated using a linear mixed-effects model. Worst skin toxicity was defined in separate models as a subgroup variable or as a measure over time.
Regardless of analysis method, there were no statistically significant differences between the panitumumab and comparator arms in any of the studies in terms of change in HSI or OHR scores. There were no statistically significant differences in QoL outcomes between patients with worst skin toxicity grade <3 and those with grade ≥3. In addition, there were no statistically significant differences between the panitumumab and comparator arms in subgroups of patients with worst skin toxicity of grade <3 and ≥3.
Addition of panitumumab to chemotherapy in RAS wild-type mCRC has no statistically significant negative effect on overall QoL, despite skin toxicity. Skin toxicity of worst grade ≥3 appeared to have similar impact on QoL as skin toxicity of grade <3.
Supplementary material 1 (DOCX 33 kb)11136_2016_1288_MOESM1_ESM.docx
Yarom, N., & Jonker, D. J. (2011). The role of the epidermal growth factor receptor in the mechanism and treatment of colorectal cancer. Discovery Medicine, 11, 95–105. PubMed
Peeters, M., Oliner, K. S., Price, T. J., Cervantes, A., Sobrero, A. F., Ducreux, M., et al. (2014). Updated analysis of KRAS/NRAS and BRAF mutations in study 20050181 of panitumumab (pmab) plus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC). Journal of Clinical Oncology, 32(Suppl. 5), Abstract #3568.
Patterson, S. D., Peeters, M., Siena, S., Van Cutsem, E., Humblet, Y., Van Laethem, J.-L., et al. (2013). Comprehensive analysis of KRAS and NRAS mutations as predictive biomarkers for single agent panitumumab (pmab) response in a randomized, phase III metastatic colorectal cancer (mCRC) study (20020408). Journal of Clinical Oncology, 13(Suppl. 15), Abstract #3617.
Schwartzberg, L. S., Rivera, F., Karthaus, M., Fasola, G., Canon, J. L., Hecht, J. R., et al. (2014). PEAK: A randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. Journal of Clinical Oncology, 32, 2240–2247. CrossRefPubMed
Amgen Europe B.V. (2015). Vectibix. EPAR product information. Breda: Amgen Europe B.V.
Boyd, K. A., Briggs, A. H., Paul, J., Iveson, T., Midgely, R., Harkin, A., et al. (2011). Analysis of adverse events and quality of life data for an economic evaluation of adjuvant chemotherapy in colorectal cancer: When can we stop collecting? Trials, 12(Suppl. 1), A41 (Abstract).
Russi, E. G., Moretto, F., Rampino, M., Benasso, M., Bacigalupo, A., De Sanctis, V., et al. (2015). Acute skin toxicity management in head and neck cancer patients treated with radiotherapy and chemotherapy or EGFR inhibitors: Literature review and consensus. Critical Reviews in Oncology/Hematology, 96, 167–182. CrossRefPubMed
American Cancer Society. Chemotherapy principles. 2015. http://www.cancer.org/acs/groups/cid/documents/webcontent/002995-pdf.pdf. Accessed 23 June 2015.
Douillard, J. Y., Siena, S., Cassidy, J., Tabernero, J., Burkes, R., Barugel, M., et al. (2010). Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study. Journal of Clinical Oncology, 28, 4697–4705. CrossRefPubMed
Peeters, M., Oliner, K. S., Price, T. J., Cervantes, A., Sobrero, A. F., Ducreux, M., et al. (2014). Analysis of KRAS/NRAS mutations in phase 3 study 20050181 of panitumumab (pmab) plus FOLFIRI versus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC). Journal of Clinical Oncology, 32(Suppl. 3), Abstract #LBA387.
Van Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., et al. (2007). Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. Journal of Clinical Oncology, 25, 1658–1664. CrossRefPubMed
Peeters, M., Price, T. J., Cervantes, A., Sobrero, A. F., Ducreux, M., Hotko, Y., et al. (2010). Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. Journal of Clinical Oncology, 28, 4706–4713. CrossRefPubMed
National Cancer Institute Cancer Therapy Evaluation Program (CTEP). Common terminology criteria for adverse events (CTCAE), version 3.0, DCTD, NCI, NIH, DHHS (2006). http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf. Accessed 15 February 2016.
Fitzmaurice, G. M., Laird, N., & Ware, J. H. (2011). Applied longitudinal analysis (2nd ed.). Hoboken: Wiley.
Wang, J., Hechmati, G., Dong, J., Maglinte, G. A., Barber, B., Douillard, J.-Y. (2015). Q-TWiST analysis of panitumumab plus FOLFOX4 versus FOLFOX4 alone in patients with previously untreated wild-type RAS metastatic colorectal cancer. Current Medical Research and Opinion (Epub ahead of print).
Odom, D., Barber, B., Bennett, L., Peeters, M., Zhao, Z., Kaye, J., et al. (2011). Health-related quality of life and colorectal cancer-specific symptoms in patients with chemotherapy-refractory metastatic disease treated with panitumumab. International Journal of Colorectal Disease, 26, 173–181. CrossRefPubMed
Wang, J., Zhao, Z., Barber, B., Sherrill, B., Peeters, M., & Wiezorek, J. (2011). A Q-TWiST analysis comparing panitumumab plus best supportive care (BSC) with BSC alone in patients with wild-type KRAS metastatic colorectal cancer. British Journal of Cancer, 104, 1848–1853. CrossRefPubMedPubMedCentral
Siena, S., Tabernero, J., Bodoky, G., Cunningham, D., Rivera, F., Ruff, P., et al. (2016). Quality of life during first−line FOLFOX4 ± panitumumab in RAS wild−type metastatic colorectal carcinoma: Results from a randomised controlled trial. ESMO Open, 1, e000041.
Thaler, J., Karthaus, M., Mineur, L., Greil, R., Letocha, H., Hofheinz, R., et al. (2012). Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study. BioMed Central Cancer, 12, 438. PubMedPubMedCentral
Láng, I., Köhne, C. H., Folprecht, G., Rougier, P., Curran, D., Hitre, E., et al. (2013). Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin. European Journal of Cancer, 49, 439–448. CrossRefPubMed
- Skin toxicity and quality of life during treatment with panitumumab for RAS wild-type metastatic colorectal carcinoma: results from three randomised clinical trials
- Springer International Publishing